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[£48,554]). Admissions for other drug-related toxicities
were lower for pemetrexed (17 admissions [£15,020]) vs.
docetaxel (31 admissions [£27,091]). Average cost of
these hospitalisations was £75 and £274 for pemetrexed
and docetaxel, respectively. More patients on the peme-
trexed arm received red blood cell transfusions (17% vs.
12%), however, more patients on the docetaxel arm
received erythropoietin (10% vs. 7%). Patients on the
pemetrexed arm received fewer courses of parenteral
antibiotics and GCSF and required fewer hospital admis-
sions and days. Total average costs were £159 and £484
for the pemetrexed and docetaxel arms, respectively.
CONCLUSIONS: In the second-line treatment of
NSCLC, pemetrexed offers similar efﬁcacy to docetaxel
but better tolerability. This results in less expensive man-
agement of chemotherapy-related adverse events, primar-
ily through reduced hospitalisation.
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OBJECTIVE: Estimate and compare resource use and
costs associated with RBC transfusions in the manage-
ment of anaemia among cancer patients treated with
chemotherapy in one French and one Austrian setting.
METHOD: The same ABC study protocol was used:
structured interviews were held with key personnel at the
oncology ward to obtain a detailed overview of the activ-
ities, frequencies, resource use and related links to other
hospital departments when administering RBC transfu-
sions. Sequential tasks were grouped into activity blocks
with clear start- and end-points. A trained centre nurse
measured the time devoted to each activity block with a
stopwatch. The time devoted to isolated or less frequent
activities was estimated from interviews. Unit costs for
personnel time, supplies, laboratory tests, waste manage-
ment and overhead costs were collected in each centre.
RESULTS: Seven transfusions were observed in the
French and eight in the Austrian setting. The average
duration per transfusion, including all the observed and
non-observed activities performed by the different health
care professionals (physician, blood bank physician,
nurse, auxiliary nurse, receptionist and lab technician)
was 3 hours 15min (min: 1h50; max: 4h50) in the Aus-
trian setting and 4 hours 31min (min: 2h35; max: 6h39)
in the French setting. A different organisational structure
in the blood transfusion centres explains the time differ-
ence observed. The average cost per transfusion was €361
(min: €315; max: €411) in Austria and €396 (min: €224;
max: €452) in France. Personnel costs in Austria were
higher than in France, but the ofﬁcial listed hospital price
for 1 RBC blood pack in Austria was considerably lower
(€115 versus €166). CONCLUSION: Time involved in
one RBC transfusion among anaemic cancer patients 
may differ substantially between centres due to different
organisational structures. Comparing the average cost per
transfusion between countries may not reﬂect these dif-
ferences when important unit cost variations between
European countries exist.
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OBJECTIVES: Britain has one of the highest breast
cancer rates in the world with around 36,000 women
newly diagnosed each year. With improving survival rates
on average 90% of women are still alive 5 years later. The
ATAC trial (median follow-up 47.2 months) conﬁrmed
that anastrozole resulted in a 18% reduction in the risk
of disease recurrence relative to tamoxifen in this popu-
lation. Our study aimed to identify the budget impact of
anastrozole compared to tamoxifen in postmenopausal
women with early breast cancer based on alternative sce-
narios of uptake over three years from the NHS perspec-
tive. METHODS: The budget impact model was based
on a modelled cost-effectiveness analysis of the ATAC
trial data. Published UK data was used to estimate the
treatment eligible population each year. Different scenar-
ios about uptake were deﬁned and the net budgetary
effects calculated. Costs were discounted at 6% annu-
ally. Probabilistic sensitivity analysis was undertaken.
RESULTS: For a total number of around 13,200 HR +
EBC patients each year the cost of drug treatment with
tamoxifen is estimated to be £64.6 million. Under the
projected likely scenario of uptake reaching 35% by
2006, the net present value of the incremental drug costs
with anastrozole will amount to £18.4 million. This is
offset by £3.4 million by avoiding breast cancer recur-
rences, AEs and follow-up costs. The model is sensitive
to the rate of uptake. CONCLUSIONS: The budgetary
impact of anastrozole for all available patients is less 
than 7% of the annual amount spent on breast cancer in
the UK. If the subpopulation with high risk of throm-
boembolic and cardiovascular disease were included the
impact will be lower. Other technologies with similar
budget impact have been approved but NICE. Accompa-
nying the cost-effectiveness analysis the budget impact is
going to be an important input into the forthcoming
policy decision about the adoption of anastrozole in EBC
patients.
